<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01384734</url>
  </required_header>
  <id_info>
    <org_study_id>205889</org_study_id>
    <secondary_id>AI438-011</secondary_id>
    <nct_id>NCT01384734</nct_id>
  </id_info>
  <brief_title>HIV Attachment Inhibitor to Treat Human Immunodeficiency Virus 1 (HIV-1) Infections</brief_title>
  <official_title>A Phase IIb Randomized, Controlled, Partially-Blinded Trial to Investigate Safety, Efficacy and Dose-Response of BMS-663068 in Treatment-experienced HIV-1 Subjects, Followed by an Open-Label Period on the Recommended Dose</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ViiV Healthcare</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ViiV Healthcare</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety, efficacy, tolerability and
      pharmacokinetics of four doses of BMS-663068 with Raltegravir (RAL) + Tenofovir Disoproxil
      Fumarate (TDF). At least 1 dose of BMS-663068 can be identified which is safe, well
      tolerated, and efficacious when combined with RAL + TDF for treatment-experienced HIV-1
      infected subjects. PHENOSENSEÂ® is a registered trademark of Monogram Biosciences.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Masking: Double-blind for BMS-6630368 treatment groups until the Week 24 Primary Endpoint
      analysis, then open label. The reference groups is all open-label.

      Arms: 5 (4 BMS-663068 treatment groups and 1 reference group)

      Intervention Model: Parallel (with unblinding after the Week 24 primary endpoint analysis)
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 26, 2011</start_date>
  <completion_date type="Actual">May 12, 2017</completion_date>
  <primary_completion_date type="Actual">February 18, 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of subjects with plasma HIV-1 ribonucleic acid (RNA) &lt; 50 c/mL</measure>
    <time_frame>At Week 24</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of Serious Adverse Events (SAEs) and discontinuations due to Adverse Events (AEs)</measure>
    <time_frame>Up to Week 24</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes from monotherapy baseline (Monotherapy Day 1) in log10 HIV ribonucleic acid (RNA) by study day during monotherapy</measure>
    <time_frame>Baseline and at Monotherapy Day 7</time_frame>
    <description>Monotherapy Substudy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum decrease from monotherapy baseline in log10 plasma HIV-1 RNA during monotherapy</measure>
    <time_frame>Baseline and at Monotherapy Day 7</time_frame>
    <description>Monotherapy Substudy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with plasma HIV-1 RNA &lt; 50 c/mL at baseline (Combination Therapy Day 1)</measure>
    <time_frame>Baseline and at Monotherapy Day 7</time_frame>
    <description>Monotherapy Substudy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of Serious Adverse Events (SAEs) and discontinuations due to Adverse Events (AEs) during monotherapy</measure>
    <time_frame>At Monotherapy Day 7</time_frame>
    <description>Monotherapy Substudy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from monotherapy baseline in CD4+ and CD8+ T-cell counts and percents by study day during monotherapy</measure>
    <time_frame>Baseline and at Monotherapy Day 7</time_frame>
    <description>Monotherapy Substudy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with plasma HIV-1 RNA &lt; 50 c/mL</measure>
    <time_frame>Week 48</time_frame>
    <description>Primary Study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of SAEs and discontinuations due to AEs</measure>
    <time_frame>Week 48</time_frame>
    <description>Primary Study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of SAEs and discontinuations due to AE</measure>
    <time_frame>Week 96</time_frame>
    <description>Primary Study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with plasma HIV-1 RNA &lt; 50 c/mL.</measure>
    <time_frame>Week 96</time_frame>
    <description>Primary Study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in CD4+ T-cell count</measure>
    <time_frame>Baseline and Week 24</time_frame>
    <description>Primary Study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in CD4+ T-cell count.</measure>
    <time_frame>Baseline and Week 48</time_frame>
    <description>Primary Study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in CD4+ T-cell count,</measure>
    <time_frame>Baseline and Week 96</time_frame>
    <description>Primary Study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of newly-emergent genotypic substitutions among subjects with virologic failure</measure>
    <time_frame>Week 24</time_frame>
    <description>Primary Study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of newly-emergent genotypic substitutions among subjects with virologic failure.</measure>
    <time_frame>Week 48</time_frame>
    <description>Primary Study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of newly-emergent genotypic substitutions among subjects with virologic failure,</measure>
    <time_frame>Week 96</time_frame>
    <description>Primary Study</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">254</enrollment>
  <condition>Infection, Human Immunodeficiency Virus</condition>
  <arm_group>
    <arm_group_label>Arm A: BMS-663068 (400mg) + Raltegravir + Tenofovir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment Group 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B: BMS-663068 (800 mg) + Raltegravir + Tenofovir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment Group 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C: BMS-663068 (600 mg) + Raltegravir + Tenofovir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment Group 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm D: BMS-663068 (1200 mg) + Raltegravir + Tenofovir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment Group 4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm E: Atazanavir + Ritonavir + Raltegravir + Tenofovir</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment Group 1 (reference arm)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-663068 400 mg</intervention_name>
    <description>Tablets, Oral, 400 mg, twice daily (BID), 24+ weeks until optimal dose is selected, or 96 weeks if optimal dose</description>
    <arm_group_label>Arm A: BMS-663068 (400mg) + Raltegravir + Tenofovir</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-663068 800 mg</intervention_name>
    <description>Tablets, Oral, 800 mg, twice daily (BID), 24+ weeks until optimal dose is selected, or 96 weeks if optimal dose</description>
    <arm_group_label>Arm B: BMS-663068 (800 mg) + Raltegravir + Tenofovir</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-663068 600 mg</intervention_name>
    <description>Tablets, Oral, 600 mg, once daily (QD), 24+ weeks until optimal dose is selected, or 96 weeks if optimal dose</description>
    <arm_group_label>Arm C: BMS-663068 (600 mg) + Raltegravir + Tenofovir</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-663068 1200 mg</intervention_name>
    <description>Tablets, Oral, 1200 mg, once daily (QD), 24+ weeks until optimal dose is selected, or 96 weeks if optimal dose</description>
    <arm_group_label>Arm D: BMS-663068 (1200 mg) + Raltegravir + Tenofovir</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Raltegravir 400 mg</intervention_name>
    <description>Tablets, Oral, 400 mg, twice daily (BID), 24+ weeks until optimal dose is selected, or 96 weeks if optimal dose</description>
    <arm_group_label>Arm C: BMS-663068 (600 mg) + Raltegravir + Tenofovir</arm_group_label>
    <arm_group_label>Arm D: BMS-663068 (1200 mg) + Raltegravir + Tenofovir</arm_group_label>
    <arm_group_label>Arm A: BMS-663068 (400mg) + Raltegravir + Tenofovir</arm_group_label>
    <arm_group_label>Arm E: Atazanavir + Ritonavir + Raltegravir + Tenofovir</arm_group_label>
    <arm_group_label>Arm B: BMS-663068 (800 mg) + Raltegravir + Tenofovir</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenofovir 300 mg</intervention_name>
    <description>Tablets, Oral, 300 mg, Once daily (QD), 24+ weeks until optimal dose is selected, or 96 weeks if optimal dose</description>
    <arm_group_label>Arm C: BMS-663068 (600 mg) + Raltegravir + Tenofovir</arm_group_label>
    <arm_group_label>Arm D: BMS-663068 (1200 mg) + Raltegravir + Tenofovir</arm_group_label>
    <arm_group_label>Arm A: BMS-663068 (400mg) + Raltegravir + Tenofovir</arm_group_label>
    <arm_group_label>Arm E: Atazanavir + Ritonavir + Raltegravir + Tenofovir</arm_group_label>
    <arm_group_label>Arm B: BMS-663068 (800 mg) + Raltegravir + Tenofovir</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ritonavir 100 mg</intervention_name>
    <description>Tablets, Oral, 100 mg, Once daily, 96 weeks</description>
    <arm_group_label>Arm E: Atazanavir + Ritonavir + Raltegravir + Tenofovir</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atazanavir 300 mg</intervention_name>
    <description>Capsules, Oral, 300 mg, Once daily, 96 weeks</description>
    <arm_group_label>Arm E: Atazanavir + Ritonavir + Raltegravir + Tenofovir</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Plasma HIV-1 RNA â¥ 1000 copies/ml at Screening

          -  Treatment experience with antiretroviral therapies (excluding integrase inhibitors)

          -  Screening PHENOSENSE Entry indicating BMS-626529 inhibitory concentration (IC)50 &lt; 0.1
             Î¼M

          -  Cluster of differentiation (CD)4+ T-cell count &gt; 50 cells/mm3

        Exclusion Criteria:

          -  History (or evidence at Screening) of genotypic resistance to any component of the
             study regimen [ Tenofovir Disoproxil Fumarate (TDF), Atazanavir (ATV), Raltegravir
             (RAL)]

          -  Certain laboratory and electrocardiogram (ECG) values
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>ViiV Healthcare</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Coral Gables</city>
        <state>Florida</state>
        <zip>33134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30312</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10008</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267-0405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Longview</city>
        <state>Texas</state>
        <zip>75605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ciudad de Buenos Aires</city>
        <state>Buenos Aires</state>
        <zip>C1202ABB</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Rosario</city>
        <state>Santa Fe</state>
        <zip>2000</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1141ACG</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1426EGR</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>CÃ³rdoba</city>
        <zip>X5000JJS</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Rosario</city>
        <zip>S2000CXP</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bogota</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bogoto</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>BogotÃ¡</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bonn</city>
        <state>Nordrhein-Westfalen</state>
        <zip>53127</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>12157</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hamburg</city>
        <zip>20099</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>MÃ¼nchen</city>
        <zip>80336</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <zip>44280</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Zapopan</city>
        <state>Jalisco</state>
        <zip>45170</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>San Luis Potosi</city>
        <state>San Luis PotosÃ­</state>
        <zip>78240</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Aguascalientes</city>
        <zip>20230</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>DF</city>
        <zip>14000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Distrito Federal</city>
        <zip>03720</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Mexico City</city>
        <zip>3100</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Iquitos</city>
        <state>Loreto</state>
        <zip>Iqui 01</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lima</city>
        <zip>13</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lima</city>
        <zip>1</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lima</city>
        <zip>32</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lima</city>
        <zip>4</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lima</city>
        <zip>Lima 11</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lima</city>
        <zip>Lima 31</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bucharest</city>
        <zip>021105</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Constanta</city>
        <zip>900709</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Craiova</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Iasi</city>
        <zip>700116</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>191167</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Smolensk</city>
        <zip>214006</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>St. Petersburg</city>
        <zip>190103</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>St. Petersburg</city>
        <zip>196645</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Dundee</city>
        <state>KwaZulu- Natal</state>
        <zip>3000</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Durban</city>
        <zip>4001</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Johannesburg</city>
        <zip>2010</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Observatory, Cape Town</city>
        <zip>7925</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Badalona</city>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>CÃ³rdoba</city>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Colombia</country>
    <country>Germany</country>
    <country>Mexico</country>
    <country>Peru</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 23, 2011</study_first_submitted>
  <study_first_submitted_qc>June 28, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 29, 2011</study_first_posted>
  <last_update_submitted>May 10, 2018</last_update_submitted>
  <last_update_submitted_qc>May 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Atazanavir Sulfate</mesh_term>
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Raltegravir Potassium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

